secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-01-16T23:59:59+00:00
Accession:  0001104659-25-003950
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics appoints Dr. Rajiv Patni to Board of Directors
-------------------------------------------------------------------

- Board increased from seven to eight directors on January 15, 2025.
- Dr. Patni appointed as Class II director, term expiring at 2026 annual meeting.
- He brings experience as CEO of Judo Bio and former CRO at Reata Pharmaceuticals.
- Granted option to purchase 44,000 shares at $0.3465, vesting over three years.
- Eligible for standard non-employee director compensation program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925003950/0001104659-25-003950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925003950/tm253320d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-003950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer